Cucurbitacin B enhances apoptosis in gefitinib resistant non-small cell lung cancer by modulating the miR-17-5p/STAT3 axis

Tyrosine kinase inhibitors, such as gefitinib, are currently widely used as targeted therapeutics for non-small cell lung cancer (NSCLC). Although drug resistance has become a major obstacle to successful treatment, mechanisms underlying resistance to gefitinib remain unclear. Therefore, the present...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Baodan, Zheng, Lixia, Tang, Huiqin, Wang, Weixin, Lin, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383048/
https://www.ncbi.nlm.nih.gov/pubmed/34396444
http://dx.doi.org/10.3892/mmr.2021.12349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383048/
https://www.ncbi.nlm.nih.gov/pubmed/34396444
http://dx.doi.org/10.3892/mmr.2021.12349

Ejemplares similares